Humira adalimumab: Phase III data

In the 2-year, double-blind, U.S. Phase III PREMIER trial in 799 patients comparing Humira in

Read the full 151 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE